"The Cancer Moonshot Initiative’s mission of speeding cures for the hundreds of cancers we treat is much more complex than putting a man on the moon."
President Barack Obama’s announcement of a Cancer Moonshot Initiative, led by Vice President Joe Biden. In 1962, President John F. Kennedy said the United States would put a man on the moon—and a mere seven years later, we did. Already, we are seeing solutions which allow cancer providers to improve the quality and value of care.
Howard Urnovitz, CEO of Chronix Biomedical, commenting on our cancer diagnostics tests and a new video released, send a message to US VP Joe Biden: “Your rocket is ready, Sir.”
The CNI Tests are #TheTurningPointInCancerFight.
See more about Cancer Moonshot at: http://www.futureofpersonalhealth.com/prevention-and-treatment/making-the-cancer-moonshot-a-reality?et_cid=38472645&et_rid=1614916882&linkid=Making+the+Cancer+Moonshot+a+Reality
Exactly 20 years ago, on 4th of October 1996, Howard Urnovitz, founder and CEO of Chronix Biomedical, an innovative biomedical company from Palo Alto (California, US), has applied for a Patent, which was the result of the medical study on health problems, that American soldiers faced returning from the first Gulf war in Iraq (the so-called: GWI – “Gulf war Ilnesses”). Urnovitz has discovered, 5 years before the discovery of human genome, that the study on DNA fragments of the chromosomes may be used in the future “to monitor the success of treatment of disease”.
In the same 1996, US Food and Drug Administration (FDA) officially approved a test to measure the level of HIV virus in the blood (a viral load test), which was the revolution in the treatment of AIDS. Eventually, the test has led to a situation where AIDS has changed from deadly into a chronic disease. The ability to measure the level of HIV in the body, meant that doctors could choose the appropriate methods of treatment and check their effectiveness. As a result, no one else dies of AIDS unnecessarily any more.
The year 2016 brings a similar revolution in the fight against cancer. Chronix Biomedical has created an innovative method of diagnosis of cancer – the CNI test. Similarly to HIV testing, Chronix tests measure “the amount of cancer in the blood,” by detecting gains and losses of cell free DNA fragments in the blood. The result is indicated as the CNI number (Copy Number Imbalance), which shows how much cancer is in the body . Chronix tests allow to detect cancer at an early stage of the disease as well as to monitor the effectiveness of cancer treatment. We are at the edge of a turning point in the fight against the development of malignant tumors.
Therefore, we have started an open Facebook event: #TheTurningPointInCancerFight
Our goal is education of cancer diagnostics importance, both as a monitoring and early prediction tool. We invite individuals and organizations to join us in the fight against cancer. Please share the information.
The London General Practice is delighted to have partnered with Advanced Cancer Diagnostics and Chronix Biomedical to provide a revolutionary cancer screening programme.
For the first time, we can now look for cancer in the entire body rather than only employing the traditional, but still relevant and highly valuable, scanning and biopsy methods carried out on presentation of symptoms.
With the Chronix blood test we can now screen those with risk factors associated with developing cancer. This is specifically relevant to those with concerns about breast, prostate or colorectal cancers, or those that are seeking clarity of their cancer risk.
The whole article you can see here: http://www.thelondongeneralpractice.com/advanced-cancer-screening/
Chronix Biomedical is offering a laboratory developed blood test that is being used as a supplementary evaluation to prostate cancer screening. This evaluation test assists clinicians in the decision making process of whether a patient with an elevated PSA, suspicious MRI or DRE should be sent for a tissue biopsy. The Second Opinion™ Prostate Cancer Evaluation Test is designed to bring down the unacceptably high number of false positives associated with PSA testing.Sign up to Learn More